

EU-Japan Webinar Series on COVID-19 Research and Innovation

Professor Peter Piot


London School of Hygiene & Tropical Medicine

17 September 2020

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



240+ COVID-19 vaccine candidates in the pipeline



Massive investments

- **Big investments from companies** developing vaccines (e.g. AstraZeneca, GSK, J&J, Merck, Pfizer, and Sanofi)
- The European Commission, Japan, and partners raised **€15.9 billion** as part of the **Coronavirus Global Response**
- **US Operation Warp Speed programme** has announced **more than US\$10 billion** to advance vaccine R&D
- **Coalition for Epidemic Preparedness Innovations** portfolio includes 8 clinical candidates and is being advanced under **COVAX**

Vaccine Pipeline: Phases I-III

241



vaccine candidates

42



in clinical testing



Phase III	<ul style="list-style-type: none"> Moderna/NIAID CanSino Biological Inc/Beijing Institute of Biotechnology Gamaleya Research Institute Janssen Pharmaceutical Companies/Beth Israel Deaconess Medical Center 	<ul style="list-style-type: none"> University of Oxford/AstraZeneca Beijing Institute of Biological Products/Sinopharm Sinovac/Instituto Butantan Wuhan Institute of Biological Products/Sinopharm
Phase II/III	<ul style="list-style-type: none"> BioNTech/Fosun Pharma/Pfizer 	
Phase II	<ul style="list-style-type: none"> CureVac Anhui Zhifei Longcom Biopharmaceutical/Chinese Academy of Sciences 	<ul style="list-style-type: none"> Novavax
Phase I/II	<ul style="list-style-type: none"> Arcturus/Duke-NUS Genexine Consortium Inovio Pharmaceuticals/International Vaccine Institute Osaka University/AnGes/Takara Bio Zydus Cadila Healthcare Limited (DNA) Bharat Biotech/ICMR/National Institute of Virology 	<ul style="list-style-type: none"> Institute of Medical Biology/Chinese Academy of Medical Sciences Research Institute for Biological Safety Problems (inactivated) FBRI SRC VB VECTOR/Rospotrebnadzor, Koltsovo/(peptide) Instituto Finlay de Vacunas Kentucky Bioprocessing Inc Sanofi Pasteur/GSK
Phase I	<ul style="list-style-type: none"> Imperial College London PLA Academy of Military Sciences/Walvax Biotech Symvivo ReiThera/Leukocare/Univercells Beijing Wantai Biological Pharmacy/Xiamen University Institut Pasteur/Themis/University of Pittsburg/Merck Merck Adimmune Corporation Clover Biopharmaceuticals Inc/GSK/Dynavax 	<ul style="list-style-type: none"> Covaxx/University of Nebraska Medical Center Medigen Vaccine Biologics Corporation/NAID/Dynavax University of Queensland/CSL/Seqirus Vaxine Pty/Medytox West China Hospital/Sichuan University Medicago Inc/GSK/Dynavax Aivita Biomedical Inc Shenzhen Geno-Immune Medical Institute/(modified APC) Shenzhen Geno-Immune Medical Institute/(modified DC)

COVID-19 vaccine initiatives in Europe and Africa

ACT-ACCELERATOR

Total investment needed
US\$ 31.3 BILLION



Vaccines: CEPI, Gavi
Therapeutics: Unitaid, WHO
Diagnostics: FIND, The Global Fund


Coronavirus Global Response



#UnitedAgainstCoronavirus · #StrongerTogether · #GlobalResponse

COVAX: Ensuring global equitable access to COVID-19 vaccines

CEPI Gavi WHO




Home / News / Press Releases

African Union Commission launches Consortium for COVID-19 Vaccine Clinical Trial

Will Vaccines end the pandemic?

Challenges ahead for a safe and effective COVID-19 vaccine:

1. Will it work? For how long?
2. Will it be safe?
3. Will there be enough?
4. Who gets it first?
5. Will people accept it?

THE WALL STREET JOURNAL

Drug-Company CEOs Sign Pledge on Covid-19 Vaccine

Statement from nine firms aims to address concerns over a rush to mass vaccination

Sep 8th 2020

The Economist

Responding to covid-19

Tedros Adhanom on why vaccine nationalism harms efforts to halt the pandemic

There are no silver bullets!

THE LANCET


ARTICLES | ONLINE FIRST

PDF

Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling study

Alexandre de Figueiredo, PhD · Clarissa Simas, MSc · Emilie Karafilakis, MSc · Pauline Paterson, PhD · Prof Heidi J. Larson, PhD · Show footnotes

Published: September 10, 2020 · DOI: [https://doi.org/10.1016/S0140-6736\(20\)31558-0](https://doi.org/10.1016/S0140-6736(20)31558-0) · Check for updates



Societies living with COVID-19

- **Future waves**
- **Series of outbreaks** - No time to lose!
- Safe spaces for **vulnerable communities**
- Long-term **care for survivors**
- **Social sciences** and **epidemiology**
- **Research** and **innovation**
- **Wider health impacts** of COVID-19 response
- **Mental health** and wellbeing
- **Healthy longevity** and social care
- Acute and long-term **social and economic costs**
- Rethinking **how we work**
- **Urban planning**
- **Access to internet**
- Are we ready for **the next pandemic?**

No country is safe,
unless every country
is safe